1. Zinc Status Alters Alzheimer's Disease Progression through NLRP3-Dependent Inflammation
- Author
-
Alison E. Mather, Jack Rivers-Auty, Harry G. Spence, Christopher Hoyle, Michael J.D. Daniels, Shi Yu, Margaret Jane Gordon, James Cook, David Brough, Paul T. Kennedy, John H. Beattie, Amy Bradley, Victor S. Tapia, Ruth Peters, Samuel Drinkall, Te-Chen Tzeng, Claire S. White, Catherine B. Lawrence, and Jack Peter Green
- Subjects
0301 basic medicine ,Adult ,Male ,chemistry.chemical_element ,microglia ,Inflammation ,Mice, Transgenic ,Zinc ,Disease ,03 medical and health sciences ,Mice ,0302 clinical medicine ,NLRP3 ,Alzheimer Disease ,Neurobiology of Disease ,NLR Family, Pyrin Domain-Containing 3 Protein ,Medicine ,Animals ,Humans ,Cognitive Dysfunction ,Risk factor ,Cognitive decline ,Research Articles ,Cells, Cultured ,APP/PS1 ,Aged ,Microglia ,business.industry ,General Neuroscience ,zinc ,Alzheimer's disease ,Middle Aged ,medicine.disease ,Mice, Inbred C57BL ,Malnutrition ,030104 developmental biology ,medicine.anatomical_structure ,chemistry ,inflammation ,Immunology ,Dietary Supplements ,Zinc deficiency ,Disease Progression ,Female ,medicine.symptom ,Inflammation Mediators ,business ,030217 neurology & neurosurgery ,Follow-Up Studies - Abstract
Alzheimer's disease is a devastating neurodegenerative disease with a dramatically increasing prevalence and no disease-modifying treatment. Inflammatory lifestyle factors increase the risk of developing Alzheimer's disease. Zinc deficiency is the most prevalent malnutrition in the world and may be a risk factor for Alzheimer's disease potentially through enhanced inflammation, although evidence for this is limited. Here we provide epidemiological evidence suggesting that zinc supplementation was associated with reduced risk and slower cognitive decline, in people with Alzheimer's disease and mild cognitive impairment. Using the APP/PS1 mouse model of Alzheimer's disease fed a control (35 mg/kg zinc) or diet deficient in zinc (3 mg/kg zinc), we determined that zinc deficiency accelerated Alzheimer's-like memory deficits without modifying amyloid β plaque burden in the brains of male mice. The NLRP3-inflammasome complex is one of the most important regulators of inflammation, and we show here that zinc deficiency in immune cells, including microglia, potentiated NLRP3 responses to inflammatory stimuliin vitro, including amyloid oligomers, while zinc supplementation inhibited NLRP3 activation.APP/PS1mice deficient in NLRP3 were protected against the accelerated cognitive decline with zinc deficiency. Collectively, this research suggests that zinc status is linked to inflammatory reactivity and may be modified in people to reduce the risk and slow the progression of Alzheimer's disease.SIGNIFICANCE STATEMENTAlzheimer's disease is a common condition mostly affecting the elderly. Zinc deficiency is also a global problem, especially in the elderly and also in people with Alzheimer's disease. Zinc deficiency contributes to many clinical disorders, including immune dysfunction. Inflammation is known to contribute to the risk and progression of Alzheimer's disease; thus, we hypothesized that zinc status would affect Alzheimer's disease progression. Here we show that zinc supplementation reduced the prevalence and symptomatic decline in people with Alzheimer's disease. In an animal model of Alzheimer's disease, zinc deficiency worsened cognitive decline because of an enhancement in NLRP3-driven inflammation. Overall, our data suggest that zinc status affects Alzheimer's disease progression, and that zinc supplementation could slow the rate of cognitive decline.
- Published
- 2021